Yritysten teknologisen keskittymisen tutkiminen patenttianalyysin avulla Case: Apple, HTC, Nokia, Samsung

Työssä tutkitaan neljän matkapuhelinvalmistajan teknologista keskittymistä patenttianalyysin avulla. Tavoitteena on tutkia, onko yritysten patentoinnissa eroja sekä mihin eri teknologian osa-alueisiin yritykset patentoivat ja mihin eivät. Tavoitteen taustalla on selvittää, voidaanko patenttiaineistosta saada viitteitä yrityksen ydinosaamisesta. Työ koostuu kolmesta rakenteellisesta osiosta. Teoria esittelee patentit ja patenttiviittaukset. Patenttiaineisto on kerätty Lappeenrannan teknillisen yliopiston patenttipalvelimelta ja sitä on analysoitu tietokanta- sekä tilastollisen käsittelyn ohjelmalla. Tuloksista tehdyt analyysit yhdistetään teoriaan, jonka pohjalta tehdään johtopäätöksiä sekä suoritetaan vertailua yritysten kesken liittyen tutkimuskysymyksiin. Lopuksi arvioidaan aineiston ja tulosten luotettavuutta sekä esitetään mahdollisia jatkotutkimusaiheita.

Tuulivoimateollisuuden tarkastelu patenttianalyysiä hyödyntäen

Työssä luodaan katsaus tuulivoiman käyttöön historiassa sekä tuulivoiman hyödyntämiseen sähköntuotantoon nykyaikaisessa yhteiskunnassa. Lisäksi esitellään modernin kolmilapaisen tuuliturbiinin tekniikkaa. Työssä tarkastellaan kolmen suuren tuulivoimaloita valmistavien yrityksien patentointiaktiivisutta aikavälillä 2000–2010 ja patenttien lukumäärässä, maantieteellisessä vaihtelussa, tyypissä ja luokissa esiintyviä trendejä. Näiden pohjalta luodaan kokonaiskuva tuulivoiman teollisuuden kehityksestä 2000-luvun alussa ja odotetuista tulevaisuuden näkymistä. Vuosituhannen vaihteen jälkeen patentointiaktiivisuus on kasvanut tuulivoimateknologiayrityksillä. Etenkin vuonna 2007 havaitaan piikki patenttien lukumäärässä. Patentointitoiminta on keskittynyt Eurooppaan, Pohjois-Amerikkaan sekä Kiinaan. Tuulivoimateknologian voidaan olettaa kehittyvän sekä koossa että kustannustehokkuudessa.

Use of preclinical and early clinical data for dose selection of a selective estrogen receptor modulator toremifene in treatment of breast cancer

In development of human medicines, it is important to predict early and accurately enough the disease and patient population to be treated as well as the effective and safe dose range of the studied medicine. This is pursued by using preclinical research models, clinical pharmacology and early clinical studies with small sample sizes. When successful, this enables effective development of medicines and reduces unnecessary exposure of healthy subjects and patients to ineffectice or harmfull doses of experimental compounds. Toremifene is a selective estrogen receptor modulator (SERM) used for treatment of breast cancer. Its development was initiated in 1980s when selection of treatment indications and doses were based on research in cell and animal models and on noncomparative clinical studies including small number of patients. Since the early development phase, the treatment indication, the patient population and the dose range were confirmed in large comparative clinical studies in patients. Based on the currently available large and long term clinical study data the aim of this study was to investigate how the early phase studies were able to predict the treatment indication, patient population and the dose range of the SERM. As a conclusion and based on the estrogen receptor mediated mechanism of action early studies were able to predict the treatment indication, target patient population and a dose range to be studied in confirmatory clinical studies. However, comparative clinical studies are needed to optimize dose selection of the SERM in treatment of breast cancer.

Síndrome de Prune Belly

Prune Belly Syndrome is a fetal uropathy of unknown etiology with incidence of 1/35000 to 1/50000 alive been born, characterized by a classical triad: abdominal musculature congenital deficiency, bilateral criptorquidia and urinary tract malformations. The authors present a case of this rare pathology associated with a patent urachus. After complementary exams confirmed urinary tract alterations (bilateral ureterohidronefrosis and vesicoureteral reflux degree 5, besides urinary infection), the surgical approach was vesicostomy to decrease urinary infections and sepsis. Definitve surgery should be accomplished around the 12th month of life. Nowadays, the child is asymptomatic , with follow-up every two months, with return consultation bimonthly.

Excisão laparoscópica de úraco remanescente em um adulto

Abnormalities of the urachus in adults are uncommon. Urachal tract remnants, which abnormally remain patent, may be responsible for abdominal pain and infection. The persistence of the urachus can lead to several abnormalities; and the patent urachus is one of the less frequent. A 25-year-old man presented a fluid secretion from the umbilicus that bled once and had three previous episodes of abdominal pain. Magnetic Resonance Imaging revealed a patent urachus, which was confirmed by anatomopathological examination. The goal of this article is to report an urachal excision in a young adult with persistence of a patent urachus fully performed laparoscopically.

Endovascular treatment of popliteal artery aneurysm. Early and midterm results

OBJECTIVE: to evaluate the efficacy of endovascular repair of popliteal artery aneurysms on maintaining patency of the stent in the short and medium term. METHODS: this was a retrospective, descriptive and analytical study, conducted at the Integrated Vascular Surgery Service at the Hospital da Beneficência Portuguesa de São Paulo. We followed-up 15 patients with popliteal aneurysm, totaling 18 limbs, treated with stent from May 2008 to December 2012. RESULTS: the mean follow-up was 14.8 months. During this period, 61.1% of the stents were patent. The average aneurysm diameter was 2.5cm, ranging from 1.1 to 4.5cm. The average length was 5cm, ranging from 1.5 to 10 cm. In eight cases (47.1%), the lesion crossed the joint line, and in four of these occlusion of the prosthesis occurred. In 66.7% of cases, treatment was elective and only 33.3% were symptomatic patients treated on an emergency basis. The stents used were Viabahn (Gore) in 12 cases (66.7%), Fluency (Bard) in three cases (16.7%), Multilayer (Cardiatis) in two cases (11.1%) and Hemobahn (Gore) in one case (5.6%). In three cases, there was early occlusion (16.6%). During follow-up, 88.2% of patients maintained antiplatelet therapy. There was no leakage at ultrasound (endoleak). No fracture was observed in the stents. CONCLUSION: the results of this study are similar to other published series. Probably, with the development of new devices that support the mechanical characteristics found on the thighs, there will be improved performance and prognosis of endovascular restoration.

Käyttöpääoman sitoutuminen ja kiertoajat lääkejakeluketjussa

Työn tavoitteenaan oli selvittää suomalaisen lääkejakeluketjun rakenne sekä saada selkeä kuva ketjun toiminnan tehokkuudesta käyttöpääoman sitoutumisen ja kiertoaikojen osalta. Työn alussa käydään läpi teoriaa ja tutkimusta käyttöpääomasta ja sen erien kiertoajoista sekä erityisesti niiden huomioimisesta arvoketjussa. Lisäksi esitellään Suomen lääkemarkkinoiden toimintaa sekä sen toimijoita. Työn empiirinen osa suoritettiin kahdessa päävaiheessa. Ensin analysoitiin Voitto+ -ohjelmasta saatuja valittujen lääkejakeluketjun yritysten julkisia tilinpäätöstietoja ajalta 2005- 2011. Analysointi perustui käyttöpääoman sekä sen erien myyntisaamisten, ostovelkojen ja vaihto-omaisuuden kiertoaikojen laskemiseen. Ketjun yrityksiä vertailtiin toisiinsa ketjun osien keskimääräisten kiertoaikojen osalta ja saatiin selville niiden suhteellinen sijoittuminen toisiinsa nähden. Työn toisessa päävaiheessa haastateltiin esimerkkitoimijaa käsitellyn lääkejakeluketjun jokaisesta osasta: lääketehdas, tukkujakelija ja apteekki. Työssä huomattiin, että käyttöpääoman kiertoaikaan lääkejakeluketjussa vaikuttaa ensisijaisesti ketjun osan toiminnan luonne ja käyttöpääoman hallinnan tehokkuus lääkejakeluketjun toimijoiden välillä vaihtelee osaamisen ja resurssien mukaan. Ketjun eri osissa painottuvat eri käyttöpääoman erät ja ketjun toiminta on optimoitunut aikojen saatossa hyvin stabiiliin tilaan, jota ketjun jäsenillä ei näytä olevan halua muuttaa. Lääkejakeluketjun käyttöpääomaan hallintaa voitaisiin tehostaa varastonhallintaa parantamalla sekä informaation jakamisella saattamalla kysyntätiedot nopeammin koko ketjun tietoon.

The use of dietary supplements and medication among Finnish elite athletes

Background: Dietary supplements are widely used among elite athletes but the prevalence of dietary supplement use among Finnish elite athletes is largely not known. The use of asthma medication is common among athletes. In 2009, the World Anti-Doping Agency (WADA) and the International Olympic Committee (IOC) removed the need to document asthma by lung function tests before the use of inhaled β2-agonists. Data about medication use by Paralympic athletes (PA) is limited to a study conducted at the Athens Paralympics. Aims: To investigate the prevalence of the use of self-reported dietary supplements, the use of physician-prescribed medication and the prevalence of physician-diagnosed asthma and allergies among Finnish Olympic athletes (OA). In addition, the differences in the selfreported physician-prescribed medication use were compared between the Finnish Olympic and the Paralympic athletes. Subjects and methods: Two cross-sectional studies were conducted in Finnish Olympic athletes receiving financial support from the Finnish Olympic Committee in 2002 (n=446) and in 2009 (n=372) and in Finnish top-level Paralympic athletes (n= 92) receiving financial support from Finnish Paralympic committee in 2006. The results of the Paralympic study were compared with the results of the Olympic study conducted in 2009. Both Olympic and Paralympic athletes filled in a similar semi-structured questionnaires. Results: Dietary supplements were used by 81% of the athletes in 2002 and by 73% of the athletes in 2009. After adjusting for age-, sex- and type of sport, the odds ratio OR (95% confidence interval, CI) for use of any dietary supplement was significantly less in 2009 as compared with the 2002 situation (OR 0.62; 95% CI 0.43-0.90). Vitamin D was used by 0.7% of the athletes in year 2002 but by 2% in 2009 (ns, p = 0.07). The use of asthma medication increased from 10.4 % in 2002 to 13.7% in 2009 (adjusted OR 1.71; 95% CI 1.08-2.69). For example, fixed combinations of inhaled long-acting β2-agonists (LABA) and inhaled corticosteroids (ICS) were used three times more commonly in 2009 than in 2002 (OR 3.38; 95% CI 1.26-9.12). The use of any physician-prescribed medicines (48.9% vs. 33.3%, adjusted OR 1.99; 95% CI 1.13-3.51), painkilling medicines (adjusted OR 2.61; 95% CI 1.18-5.78), oral antibiotics (adjusted OR 4.10; 95% CI 1.30-12.87) and anti-epileptic medicines (adjusted OR 37.09; 95% CI 5.92-232.31) was more common among the PA than in the OA during the previous seven days. Conclusions: The use of dietary supplements is on the decline among Finnish Olympic athletes. The intake of some essential micronutrients, such as vitamin D, is suprisingly low and this may even cause harm in those well-trained athletes. The use of asthma medication, especially fixed combinations of LABAs and ICS, is clearly increasing among Finnish Olympic athletes. The use of any physician-prescribed medicine, especially those to treat chronic diseases, seems to be more common among the Paralympians than in the Olympic athletes.

Assessment of the Effects of Tribulus Terrestris on Sexual Function of Menopausal Women

Objective The aim of this study was to study the effects of Tribulus terrestris on sexual function in menopausal women. Methods This was a prospective, randomized, double-blind, placebo-controlled clinical trial that included 60 postmenopausal women with sexual dysfunction. The women were divided into two groups, placebo group and Tribulus group, and evaluated by using the Sexual Quotient-female version (SQ-F) and Female Intervention Efficacy Index (FIEI) questionnaires. Results There was no significant difference between the groups in age, age at menopause, civil status, race, and religion. In the evaluation with the SQ-F questionnaire, there were significant differences between the placebo (7.6±3.2) and Tribulus (10.2±3.2) groups in the domains of desire and sexual interest (p d" 0.001), foreplay (3.3±1.5 versus 4.2±1.0) (p d" 0.01), arousal and harmonious interaction with the partner (5.7±2.1 versus 7.2±2.6) (p d" 0.01), and comfort in sexual intercourse (6.5±2.4 versus 8.0±1.9) (p d" 0.01). There was no significant difference between the placebo and Tribulus groups in the domains of orgasm and sexual satisfaction (p = 0.28). In the FIEI questionnaire, there was a significant improvement (p < 0.001) in the domains of vaginal lubrication during coitus and/or foreplay (20 versus 83.3%), sensation in the genitalia during sexual intercourse or other stimuli (16.7 versus 76.7%), sensation in the genital region (20 versus 70%), sexual intercourse and/or other sexual stimulations (13.3 versus 43.3%), and the ability to reach orgasm (20% versus 73.3%). There was no significant difference in adverse effects between the two groups. Conclusions After 90 days of treatment, at the doses used, we found Tribulus terrestris to be effective in treating sexual problems among menopausal women.

Natural infection of calves by Anaplasma marginale in dairy herds of the Metalúrgica Region, Minas Gerais

The dynamic of natural infections by Anaplasma marginale in calves was evaluated during a period of one year on two farms located in the Metalúrgica Region, State of Minas Gerais, Brazil. Blood samples were collected weekly for rickettsemia and packed cell volume (PCV) determination. The animals born from March to July suffered the infection in October and November, independently of their age, whilst calves born from September to December acquired the infection during the first days of life. These animals presented patent rickettsemia from 30 days of life. During the patent period PCV decreased after one week of infection, ranging from 20 to 23%. It was concluded, that in the region studied, the transmission of A. marginale is influenced by climatic conditions, and that calves born during the dry season are more likely to acquire the infection when they are exposed to high transmission levels during the subsequent raining season.

Clinical evaluation of enalapril maleate and furosemide usage in dogs with degenerative myxomatous mitral valve, CHF functional class Ib

Degenerative myxomatous mitral valve (DMMV) is a heart disease of high incidence in small animal clinical medicine, affecting mainly older dogs and small breeds. Thus, a scientific investigation was performed in order to evaluate the clinical use of the medicines furosemide and enalapril maleate in dogs with this disease in CHF functional class Ib before and after the treatment was established. For this purpose 16 dogs with the given valve disease were used, separated into two groups: the first received furosemide (n=8) and the second received enalapril maleate (n=8) throughout 56 days. The dogs were evaluated in four stages (T0, T14, T28 and T56 day) in relation to clinical signs, hematological, biochemical and serum assessment, which included serum angiotensin converting enzyme (ACE) and aldosterone, as well as radiography, electrocardiography, Doppler-echocardiography and blood pressure. The results regarding the clinical, hematological and serum chemistry evaluations revealed no significant changes in both groups, but significant reductions in the values of ACE and aldosterone in the group receiving enalapril maleate were verified. The radiographic examination revealed reductions of VHS values and variable Pms wave of the electrocardiogram in both groups, but no changes in blood pressure values were identified. The echocardiogram showed a significant decrease of the variables LVDd/s in the studied groups and the FS% in animals that received only enalapril. Therefore, analysis of results showed that monotherapy based on enalapril maleate showed better efficiency of symptoms control in patients with CHF functional class Ib.

Uterine lymphangiography: comparison of two methods for locating the medial iliac lymph node

Different methods for lymphatic mapping in dogs, such as infusing tissues with vital dyes or radioactive substances, have been studied, aiming at the early detection of lymph node metastasis. Thus, one could anticipate therapeutic measures and, consequently, prolong the survival and improve the quality of life of the patients. The objectives of this experiment were to locate the nodes responsible for draining the uterine body and horns and to try to establish the relationship between the uterus and the medial iliac lymph nodes to contribute to the early diagnosis and prognosis of uterine disorders. We studied 15 female dogs divided into two groups (5 dead and 10 intraoperative ovariohysterectomy bitches). The dye used was patent blue V (Patent Bleu V®). It was observed that the iliac lymph node chain receives much of the uterine (horns) drainage. This method should be considered for safer studies of uterine sanity. This information suggests that evaluating these lymph nodes will allow correlating changes in their physiological status with uterine pathologies.

Commercialization of Modern Renewable Energy

The threat of global warming and its consequences are widely recognized, and the question of how to proceed with the long transition towards fossil fuel -neutral economies concerns many nations and people. At the same time the world’s primary energy use is predicted to increase significantly during the next decades as a result of global population and welfare increase. Improved energy efficiency and increased use of renewable energy sources in the world’s energy mix play important roles in the future energy production and consumption. The objective of this thesis is to study how novel renewable energy technologies, such as distributed small-scale bio-fueled combined heat and power production and wind power technologies could be commercialized efficiently. A wide array of attributes may contribute to the diffusion of new products. In general, the bioenergy and wind power technologies are in emerging phases, and the diffusion stage varies from country to country. The effects of firms’ technology choices, collaboration and alliances are studied in this thesis. Furthermore, the roles of national energy infrastructure and energy support schemes in the commercialization of new renewable energy products are explored. The empirical data is based on energy expert interviews, financial and patent data, and literature reviews of different case studies. The thesis comprises two parts. The first part provides an overview of the study, and the second part includes six research publications. The results reveal that small-scale bio-fueled combined heat and power production and wind power technologies are still in emerging phases in their life cycles, and energy support schemes are crucial in the market diffusion. The study contributes to earlier findings in the literature and industry by confirming that adequate energy policies and energy infrastructure are fundamental in the commercialization of novel renewable energy technologies. Firm-specific issues, including business relationships and new business models, and market-related issues will have a more significant role in the market penetration in the future, when the technologies mature and become competitive without political support schemes.

Patentointiaktiivisuuden muutos x86-prosessorivalmistajien keskuudessa vuosina 1985-2009 Case: Intel

Työssä tutkitaan x86-prosessorivalmistajien patentointiaktiivisuuden muutosta vuosina 1985 – 2009 Intelin kautta. Työn tavoitteena on selvittää syitä, jotka ovat johtaneet patentointiaktiivisuuden radikaaliin muutokseen toimialalla. Työssä esitellään patenttien tärkeys teknologiayrityksille ja miten patentointiaktiivisuus on muuttunut x86-prosessorivalmistajien keskuudessa. Työssä käsitellään patenttiteoriaa, esimerkiksi patenttijärjestelmää ja yrityksen patenttipolitiikkaa. Työssä käsitellään ei-valmistavia patenttitaloja ja luodaan katsaus niiden vaikutuksiin valmistaville yrityksille. Tämän jälkeen perehdytään yksityiskohtaisemmin teknologiajätti Inteliin. Työn tarkoitus on selvittää, onko toimialan patentointiaktiivisuus hidastumassa tai pysähtynyt. Työssä pyritään löytämään mahdollisia syitä Intelin patentointiaktiivisuuden muutokseen.